聯邦制藥
UNITED LABORATORIES

The United Laboratories Fair Pricing Policy

The United Laboratories International Holdings Limited (Stock Code: 3933.HK) ("TUL", the "Group", or "we") uphold the corporate mission of "to make life more valuable" and are committed to providing patients and customers with high-quality, efficient products and services, while continuously promoting the accessibility and affordability of medicines.

Purpose

This policy aims to improve the Group's fair pricing system and continuously promote the harmonious alignment between corporate performance and social value.

Scope of Application

1. Principle of Legality and Compliance：Comply with relevant laws, regulations and other rules and policies; strictly follow internal and external approval procedures; and ensure that public interests and the legitimate rights and interests of relevant individuals are not harmed.

2. Principle of Fairness: Based on the philosophy of product affordability, prices for products in both domestic and international markets are set fairly.

3. Principle of Accessibility: As a special type of product, the accessibility of medicines is closely related to health and human rights. The Group pays close attention to health equity in different countries and regions and is committed to providing safe and effective medicines.

4. Principle of Sustainable Innovation: A value-based product pricing strategy forms the foundation of the Group's pricing model. The pricing mechanism should support and incentivize the Group's continued investment in product innovation and research and development.

Fair Pricing Measures

1. Adopt a value-based product pricing strategy to ensure that medicine pricing reflects its value to patients, healthcare systems, and society in the local context.

2. Adopt scientific, reasonable, and differentiated pricing strategies for different product types, in alignment with the above fair pricing principles.

3. Based on the concept of product affordability, prices for products in domestic and international markets are set fairly.

(1) The Group adopts a differentiated pricing mechanism based on the development level of countries and regions. When pricing products across different countries or within different regions of the same country, factors such as the country/region's GDP, the United Nations Human Development Index, and public healthcare investment should be considered to ensure that pricing is relatively consistent across countries/regions with similar development levels and within comparable markets in the same country.
(2) Pricing strategies should be designed to enhance product accessibility based on the needs and purchasing power of patients in different countries and regions, serving a greater number of patients worldwide.

4. Regularly review the existing product pricing system and make reasonable adjustments based on market changes, cost fluctuations and policy impacts.

Review and Oversight

Relevant departments of the Group, including Medical, Marketing, Finance, and Legal, evaluate and review product pricing to ensure the effective implementation of this policy. The Group's Board of Directors oversees the execution of the Fair Pricing Policy.

Employee Training

The Group conducts relevant training on this policy for all employees every year. Employees are expected to participate in the training to understand, master and comply with all provisions of this policy.

Supplementary Provisions

Matters not covered by this policy, or those that conflict with applicable laws, regulations, or normative documents, shall be handled in accordance with the relevant laws, regulations and normative documents.